This autumn: 2026-02-26 Earnings Abstract
EPS of -$0.08 beats by $0.11
| Income of $57.58M (94.12% Y/Y) beats by $140.50K
Phathom Prescribed drugs, Inc. (PHAT) This autumn 2025 Earnings Name February 26, 2026 8:00 AM EST
Firm Members
Eric Sciorilli – Director of Enterprise Improvement & Investor Relations
Steven Basta – CEO, President & Director
Sanjeev Narula – Chief Monetary & Enterprise Officer
Convention Name Members
Kristen Kluska – Cantor Fitzgerald & Co., Analysis Division
Annabel Samimy – Stifel, Nicolaus & Firm, Integrated, Analysis Division
Anthea Li – Jefferies LLC, Analysis Division
Joseph Stringer – Needham & Firm, LLC, Analysis Division
Chase Knickerbocker – Craig-Hallum Capital Group LLC, Analysis Division
Min Lee – Guggenheim Securities, LLC, Analysis Division
Martin Auster – Raymond James & Associates, Inc., Analysis Division
Matthew Caufield – H.C. Wainwright & Co, LLC, Analysis Division
Presentation
Operator
Hi there, and welcome to Phathom Prescribed drugs Fourth Quarter and Full 12 months 2025 Earnings Outcomes Name. (Operator Directions) Please be suggested that right this moment’s name is being recorded.
With that, I want to flip the decision over to Eric Sciorilli, Phathom’s Head of Investor Relations. Please go forward.
Eric Sciorilli
Director of Enterprise Improvement & Investor Relations
Thanks, operator. Hi there, everybody, and thanks for becoming a member of us this morning to debate Phathom’s fourth quarter and full 12 months 2025 outcomes. This morning’s presentation will embrace remarks from Steve Basta, our President and CEO; and Sanjeev Narula, our Chief Monetary and Enterprise Officer.
A few notes earlier than we get began. Earlier this morning, we issued a press launch detailing the outcomes we’ll be discussing through the name. A replica of that press launch may be discovered below the Information Releases part of our company web site. Additional, the recording of right this moment’s webcast and the slides we’ll be reviewing may also be discovered on our company web site below the Occasions and Shows part.
Earlier than we start, let me remind you that we’ll be making quite a lot of forward-looking statements all through right this moment’s presentation. These forward-looking